深耕心血管疾病精准诊疗领域 北芯生命拟公开发行5700万股

Group 1 - The company, Beixin Life (688712.SH), plans to publicly issue 57 million shares, accounting for 13.67% of the total share capital after the issuance [1] - The initial strategic placement will involve 11.4 million shares, representing 20% of the total issuance, with senior management and core employees participating in a special asset management plan for 5.7 million shares, which is 10% of the total issuance [1] - The initial strategic placement by the sponsoring institution, China International Capital Corporation Wealth Securities Co., Ltd., is expected to be 2.85 million shares, or 5% of the total issuance, with a subscription amount not exceeding 40 million yuan [1] Group 2 - The company specializes in innovative medical devices for precise diagnosis and treatment of cardiovascular diseases, recognized as a national high-tech enterprise [2] - The core products include the intravascular ultrasound (IVUS) diagnostic system, the first domestically developed 60MHz high-definition IVUS product approved by the National Medical Products Administration, and the flow reserve fraction (FFR) measurement system, the first domestic product in the FFR field approved by the same authority [2] - The company reported net profits attributable to the parent company of -290 million yuan, -140 million yuan, -43.596 million yuan, and 49.4496 million yuan for the years 2022 to the first half of 2025, with an expected profit of 78 million to 88 million yuan for 2025, representing a growth of 278.91% to 301.85% compared to the previous year [2] - The total planned investment of 952 million yuan from the fundraising will be allocated to the construction of an interventional medical device industrialization base, research and development projects, and to supplement working capital [2]